Abstract

A control system of an artificial heart is disclosed herein. The control system includes a first rotary pump that replaces or assists a function of a left heart of a subject and a second rotary pump that replaces or assists a function of a right heart of the subject.

IPC Classes  ?

• A61M 60/183 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices drawing blood from both ventricles, e.g. bi-ventricular assist devices [BiVAD]
• A61M 60/196 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body replacing the entire heart, e.g. total artificial hearts [TAH]
• A61M 60/216 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller
• A61M 60/531 - Regulation using real-time patient data using blood pressure data, e.g. from blood pressure sensors
• A61M 60/546 - Regulation using real-time blood pump operational parameter data, e.g. motor current of blood flow, e.g. by adapting rotor speed

Abstract

The present invention provides: a human FVa modified polypeptide useful for a method for measuring the activity of protein S or protein C; and a new method for measuring the activity of protein S or protein C.　The present invention provides: a human FVa modified polypeptide which is a single strand, which does not have a thrombin cleavage site, and which is, in the presence of protein S, cleaved by activated protein C on the C-terminal side of an arginine residue corresponding to position 306 of human FVa; a composition or kit that includes the polypeptide and that is for testing the activity of protein S or protein C; and a method for measuring the activity of protein S or protein C by using the polypeptide.

IPC Classes  ?

• C12N 15/12 - Genes encoding animal proteins
• C07K 14/745 - Blood coagulation or fibrinolysis factors
• C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12Q 1/56 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen

Abstract

One purpose of the present disclosure is to provide a method for inspecting the presence or absence of coronary vasospasm or the onset risk thereof.　Provided is a method for inspecting the presence or absence of coronary vasospasm or the onset risk thereof, the method comprising a step for detecting an RNF213 p.R4810K gene polymorphism in a biological sample collected from a subject.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The purpose of the present invention is to provide a three-dimensional cell structure having strength that enables suturing. This method for producing a three-dimensional cell structure includes: (1) a step for preparing original cells having proliferation capability, and a culture chamber which includes a cavity having an internal space surrounded by a lower surface, an upper surface, and side surfaces, and which is formed such that the culture liquid can circulate in the internal space; (2) a step for supplying the original cells to the culture chamber; (3) a step for holding the whole culture chamber in a culture liquid; and (4) a step for culturing the original cells, integrating the original cells, the cultured cells derived therefrom, and an extracellular matrix produced during the culturing, and forming a three-dimensional cell structure that has grown to the outside of the cavity.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Embodiments disclosed herein establish the relationship between changes in cardiovascular metrics and a combination of drugs. The relationship is established based on tracing a chain of causality from drug combination to cardiovascular parameters, described by a linear relationship, and from cardiovascular parameters to cardiovascular metrics, by measuring the direction and sensitivity of the hemodynamic changes caused by the changes to the cardiovascular parameters (which in turn is caused by administration of drugs). Some embodiments model myocardial oxygen consumption — which cannot be measured directly — and also establish the relationship between hemodynamic changes to the myocardial oxygen consumption and change in one or more cardiovascular parameters. These embodiments assist in clinical decision making because the chain of causality from the dmgs to the cardiovascular metrics is both qualified and quantified; thereby reducing the level of guesswork and unknowns in deciding an optimal combination of drugs for acute heart failure patients.

IPC Classes  ?

• A61N 1/362 - Heart stimulators
• A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential

Abstract

A computer-implemented method may be provided. The method may include receiving, by a computing system, a pulmonary7 capillary7 wedge pressure and cardiac output for a human heart. The method may also include determining, by the computing system, a cardiac contractility for the human heart based on a left ventricular end-systolic elastance generated as an inverse function of a gradient of a relationship between the pulmonary7 capillary^ wedge pressure and the cardiac output, while avoiding singularities in the inverse function. The method may further include generating, by the computing system, an optimal combination of drugs to reach a target cardiac contractility from the determined cardiac contractility.

IPC Classes  ?

• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 5/026 - Measuring blood flow
• A61B 5/029 - Measuring blood output from the heart, e.g. minute volume

Abstract

This invention provides a novel preventive and/or therapeutic agent for vascular cognitive impairment, comprising, as an active ingredient, a compound that has not previously been demonstrated to have a preventive and/or therapeutic effect on vascular cognitive impairment in humans. The invention provides a preventive and/or therapeutic agent for vascular cognitive impairment in humans, comprising a polyphenol compound.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

For the purpose of accurately determining the type of arrhythmia from an image captured of the heart, this device (1) for determining the type of arrhythmia is provided with: an acquisition unit (101) for acquiring peak information about one or more peak frequencies respectively having the top one or more peak values, among peak frequencies in frequency spectra of signal waveforms showing time-series change in the area of each of left atrium, left ventricle, right atrium and right ventricle included in the captured image of the heart; and a determination unit (102) which determines the type of arrhythmia on the basis of the peak information.

IPC Classes  ?

• A61B 8/02 - Measuring pulse or heart rate

Abstract

In order to accurately determine the presence or absence of a premature contraction from a cardiac image, a premature contraction determination device (1) comprises: an acquisition unit (101) that acquires a signal waveform showing time-series changes in the area of each ventricle region and each atrium region in the cardiac image; and a determination unit (104) that compares a time interval between a time point at which the area indicated by the signal waveform reaches a reference value and a next time point at which the area indicated by the signal waveform reaches the reference value against a predetermined threshold value, and thus determines whether or not the time interval represents a premature contraction.

IPC Classes  ?

• A61B 8/02 - Measuring pulse or heart rate

Abstract

An implant device comprises a first resonance circuit (13) that has a first coil (11) and a first capacitor (12) which is connected in series or in parallel with the first coil. The capacitance of the first capacitor is set so that the resonance frequency of the first resonance circuit becomes a prescribed frequency when the implant device is embedded in the body.

IPC Classes  ?

• A61N 1/378 - Electrical supply

Abstract

The present disclosure aims to provide a manufacturing method of cellular structures. The manufacturing method comprises: preparing a cell culture container comprising: a culture surface coated with a cell non-adhesive material; and a plurality of first coated regions formed by coating the culture surface with a temperature-responsive polymer or a temperature-responsive polymer composition, wherein each of the first coated regions has a surface zeta potential of 0 mV to 50 mV; seeding cells on the culture surface; culturing the cells in a medium; performing medium replacement; and culturing the cells adhered to the first coated regions to form cellular structures.

IPC Classes  ?

• C12M 1/22 - Petri dishes
• C08F 20/56 - AcrylamideMethacrylamide
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

One purpose of the present disclosure is to provide a method for examining disease activity in Takayasu arteritis.　The method for examining disease activity in Takayasu arteritis includes a step for measuring at least one bacterium selected from the group consisting of bacteria belonging to the genera Campylobacter, Akkermansia, Fournierella, Succinatimonas, Veillonella, Lautropia, Granulicatella, Weissella, Lachnospira CAG-56 and Catenibacterium in the intestinal bacterial flora collected from a subject.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/04 - Antibacterial agents
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6869 - Methods for sequencing

Abstract

One purpose of the present disclosure is to provide a method for testing for the presence/absence of a stroke.　The method for testing for the presence/absence of a stroke includes a step of measuring the presence/absence of at least one bacterium selected from the group consisting of Streptococcus anginosus, Streptococcus mutans, Streptococcus parasanguinis, Streptococcus salivalius, and Lactobacillus fermentum in intestinal bacterial flora taken from a subject.

IPC Classes  ?

• C12Q 1/06 - Quantitative determination
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/14 - StreptococcusStaphylococcus
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present disclosure relates to methods and assays for quantifying brain-derived exosomes in biological samples from subjects before, during, and after surgery. The disclosure also provides methods and compositions for measuring and/or prognosing brain damage during surgery. The compositions and methods of the disclosure are also useful for preventing and/or treating brain damage in subjects undergoing surgery and predicting postoperative cognitive dysfunction (POCD) and/or predicting postoperative delirium (POD).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides a mechanosignaling inhibitor containing a substance capable of suppressing the expression or function of LSMEM2 as an active ingredient.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12N 15/13 - Immunoglobulins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention chiefly aims to provide a new method of detecting or determining ApoE genetic polymorphism, that is rapid and less invasive to the subject. The present invention chiefly aims to provide a new method of detecting or determining ApoE genetic polymorphism, that is rapid and less invasive to the subject. The present invention includes, for example, a method for detecting a genetic polymorphism of apolipoprotein E present in genomic DNA collected from a subject, comprising the following steps 1 to 3: 1. a step of preparing a specimen with DNA released from saliva; 2. a step of adding the followings to the specimen containing the DNA and then mixing: (1) a PCR enzyme, (2) a PCR primer pair for amplifying a nucleic acid fragment of the apolipoprotein E gene, and (3) a fluorescent labeled probe set which has oligonucleotides for detecting the genetic polymorphism of apolipoprotein E; and 3. a step of performing PCR, and measuring the fluorescence intensities according to the genetic polymorphism of apolipoprotein E from the PCR product.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6858 - Allele-specific amplification

Abstract

According to the present invention, a pharmaceutical composition for use in the treatment or prevention of peripartum cardiomyopathy, comprising an IL-6 inhibitor as an active ingredient, is provided.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

A blood pressure monitoring apparatus including a linear relationship storage portion storing previously stored linear relationships, a blood pressure measurement portion measuring a real arterial pressure of the person to be measured, a proper relationship generation portion applying, for the person to be measured, the real arterial pressure, real compression pressures, and real pulse wave propagation velocities, to thereby generate a proper relationship on the person to be measured among the real arterial pressures of the person to be measured, the real compression pressures, and the real pulse wave propagation velocities, and a blood pressure estimation portion applying, for the person to be measured, the real compression pressures and the real pulse wave propagation velocities obtained under the real compression pressures, to the proper relationship on the person to be measured, to thereby estimate the estimated arterial pressure.

IPC Classes  ?

• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

Provided is a blood pressure measurement device that makes it possible to estimate diastolic blood pressure with high accuracy. A slice β and an inclination α included in a linear regression line formula (2) for deriving a diastolic blood pressure estimation formula (5) have a constant linear relation with each other as indicated in formula (4) and are not impacted by the measured subject, and are thus unlikely to be impacted by the individual biological features of the measured subject. As a result, it is possible to measure a diastolic blood pressure value DAPe with high accuracy. In addition, the present invention has the advantage of not requiring calibration to be carried out as in the prior art wherein blood pressure estimation is performed using the pulse wave velocity PWV.

IPC Classes  ?

• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow

Abstract

Provided is a blood pressure measurement device that can accurately determine a maximum blood pressure value. A maximum blood pressure value calculation unit 88 determines a maximum blood pressure value SBP of a living body 14 on the basis of the change in a cross-correlation coefficient Φ(τ) between an upstream volume pulse wave indicated by a pulse wave signal SM1 and a downstream volume pulse wave indicated by a pulse wave signal SM3, which are sequentially obtained in the process of lowering the compression pressure of a pressure cuff 12 from a value higher than the maximum blood pressure value of the living body. A change in the cross-correlation coefficient Φ(τ) between the upstream volume pulse wave and the downstream volume pulse wave indicates that blood flow in an artery that had been blocked by the pressure cuff 14 has actually started. Thus, there are no effects from feature amounts unique to living bodies, such as vascular compliance, pulse rate, pulse pressure value, and blood pressure value, which differ per measurement subject, and it is therefore possible to increase the accuracy of determination of the maximum blood pressure value SBP of a living body.

IPC Classes  ?

• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

The present disclosure provides a method of preventing or delaying the progression from mild cognitive impairment (MCI) to dementia or a therapeutic agent therefor.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The technology relates to a method for inducing cardiomyogenesis comprising administering a therapeutically effective amount of either or both of KLF1 and KLF2b to increase the level of KLF1 and/or KLF2b in the cardiomyocytes thereby inducing cardiomyogenesis.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The purpose of the present disclosure is to provide: a method for testing for the presence/absence of hypertension, and the severity or prognosis thereof; a pathological animal model for pulmonary arterial hypertension (PAH); and a preventive or therapeutic agent for hypertension.　Provided are: a testing method for hypertension, in which regnase-1 is used as a biomarker; a PAH pathological animal model comprising a non-human animal in which regnase-1 is deleted in alveolar macrophages; and a preventive or therapeutic agent for hypertension, comprising a substance that destroys the 3'UTR stem loop structure in regnase-1 mRNA.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/12 - Antihypertensives
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a method for predicting reocclusion of an intracranial cerebral blood vessel, the method comprising: detecting whether or not a subject has a RNF213 p.R4810K polymorphism by using a sample collected from the subject; and determining that, when the subject has the RNF213 p.R4810K polymorphism and after an endovascular therapy is performed on occlusion of the intracranial cerebral blood vessel, there is a high probability of reocclusion occurring in the blood vessel that has undergone the endovascular therapy.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present invention provides an antisense oligomer having the base sequence depicted in SEQ ID NO: 26, an antisense oligomer having a base sequence resulting from substitution, deletion, insertion, or addition of 1 to 6 bases in the base sequence depicted in SEQ ID NO: 26, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, an oligonucleotide conjugate in which the antisense oligomer is bound with a molecule capable of binding to an asialoglycoprotein receptor, and a pharmaceutical composition containing the same.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 3/06 - Antihyperlipidemics

Abstract

A cerebral infarction treatment support system (100) includes a detection device (10), a display (30), and an image controller (20), and the image controller (20) includes a receiver (21) configured to receive at least one of first information (41) generated by the detection device (10) or second information (42) related to a susceptibility gene generated based on the first information (41), and a video output (22) configured to output at least one of the received first information (41) or second information (42) to the display (30).

IPC Classes  ?

• A61B 6/03 - Computed tomography [CT]
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present disclosure relates to methods and assays for quantifying brain-derived exosomes in biological samples from subjects before, during, and after surgery. The disclosure also provides methods and compositions for measuring and/or prognosing brain damage during surgery. The compositions and methods of the disclosure are also useful for preventing and/or treating brain damage in subjects undergoing surgery and predicting postoperative cognitive dysfunction (POCD) and/or predicting postoperative delirium (POD).

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/531 - Production of immunochemical test materials
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Composite particles, each of which is obtained by forming, on the surface of a gadolinium oxide-containing particle, a cover film that contains a polymer obtained by polymerizing a monomer component containing a monomer having an ethylenically unsaturated bond; a macrophage imaging agent which contains the composite particles; and a method for producing composite particles, wherein a monomer component containing a monomer having an ethylenically unsaturated bond and gadolinium oxide-containing particles are mixed with each other, and after emulsifying the thus-obtained monomer component-containing mixture in water in the presence of a surfactant and a polymerization initiator in water, the monomer component is polymerized, thereby forming cover films on the surfaces of the gadolinium oxide-containing particles.

IPC Classes  ?

• A61K 49/08 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by the carrier

Abstract

The purpose of the present disclosure is to provide an agent capable of preventing or treating severe pulmonary hypertension of degree III or IV in the classification of WHO pulmonary hypertension function, refractory pulmonary hypertension, or drug-induced pulmonary hypertension via a mechanism different from the vasodilatory action.　The arylhydro carbon receptor signal inhibitor is effective for preventing or treating severe pulmonary hypertension of degree III or IV in the classification of WHO pulmonary hypertension function, refractory pulmonary hypertension, or drug-induced pulmonary hypertension.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 9/12 - Antihypertensives
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/15 - Medicinal preparations

Abstract

The present invention is intended to provide a novel biomarker for detecting arteriosclerosis-related disease or for evaluating the stage of progression of arteriosclerosis, and specifically, the present invention relates to a marker for detecting arteriosclerosis-related disease or for evaluating the stage of progression of arteriosclerosis, comprising an NPC2 (Niemann-Pick disease type C2) protein and/or an IGFBP7 (Insulin-like growth factor-binding protein 7) protein.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present invention is intended to provide a novel biomarker capable of detecting aortic aneurysm with high sensitivity, and specifically, the present invention relates to a detection marker of aortic aneurysm, comprising an NPC2 (Niemann-Pick disease type C2) protein and/or an IGFBP7 (Insulin-like growth factor-binding protein 7) protein.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4′ and 2′ positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 3/06 - Antihyperlipidemics
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention provides a pharmaceutical composition for use in the treatment or prevention of peripartum cardiomyopathy, the pharmaceutical composition comprising an IL-6 inhibitor as an active ingredient.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives

Abstract

The present invention mainly addresses the problem of providing a novel method for detecting an ApoEgenetic polymorphism rapidly with low invasiveness for a subject. The present invention includes, for example, a method for detecting a genetic polymorphism in apolipoprotein E occurring in genomic DNA collected from a subject, the method comprising the following steps 1 to 3. 1. A step for producing a specimen containing DNA in a free form from saliva. 2. A step for adding (1) a PCR enzyme, (2) a PCR primer pair for amplifying a nucleic acid fragment of apolipoprotein E gene and (3) a fluorescent label probe set having an oligonucleotide for detecting a genetic polymorphism in apolipoprotein E to the specimen containing the DNA, and agitating the resultant mixture. 3. A step for performing PCR to produce a PCR product, and measuring a fluorescence intensity corresponding to the genetic polymorphism in apolipoprotein E from the PCR product.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

RR, actual compression pressures PcH1 and PcH2 in a low pressure section, and actual pulse wave propagation velocities PWV1 and PWV2 in the low pressure section, to a pre-stored linear relationship between a value obtained by squaring pulse wave propagation velocities PWV2 detected under a plurality of compression pressures Pc of a compression band and an arterial penetration pressure (=blood pressure AP-compression pressure Pc) in the low pressure section in which a pressure is lower than a minimum blood pressure value DAP for the living body. The blood pressure estimation unit 94 calculates an estimated blood pressure value APe for the living body by sequentially applying, to the linear relationship, actual compression pressures PcHm and actual pulse wave propagation velocities obtained in the low pressure section.

IPC Classes  ?

• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

The present invention provides an anti-human TRPV2 antibody, which recognizes an extracellular domain of human TRPV2 as an epitope, or a fragment thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/06 - Antiarrhythmics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/46 - Hybrid immunoglobulins
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/13 - Immunoglobulins
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/531 - Production of immunochemical test materials

Abstract

An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/745 - Bifidobacteria
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises producing a coated region in which a culturing surface is coated with a temperature-responsive polymer or a temperature-responsive polymer composition, forming a droplet of a cell suspension in the coated region, and performing cell culturing in the droplet. A surface zeta potential of the coated region is 0 mV to 50 mV.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises a preparation step of preparing, on a culturing surface of a cell culture container, a first coated region coated with a temperature-responsive polymer and/or a temperature-responsive polymer composition, and a plurality of second coated regions located at an edge of the first coated region and coated with a cell adhesive substance; and a seeding and culturing step of seeding cells in the first coated region and the second coated regions and culturing the cells to produce a cell structure.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12M 1/00 - Apparatus for enzymology or microbiology
• A61L 27/38 - Animal cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

This mask, to which a cartridge with a filter can be attached, is provided with: a main body which has a through-hole and which has a first opening and a second opening at the two ends in the direction of axial extension of the through-hole; a contact part which can contact the wearer's face and which has a through-hole and has a first opening and a second opening at both ends in the direction of axial extension of the through-hole, wherein the peripheral edge of the first opening of the contact part is fixed to the peripheral edge of the second opening of the main body; and a cover member which is attached so as to close the first opening of the main body and in which at least one ventilation hole is formed. Between the cover member and the first opening of the main body, a housing space is formed that houses the cartridge so as to close the through-hole of the main body.

IPC Classes  ?

• A62B 18/08 - Component parts for gas-masks or gas-helmets, e.g. windows, straps, speech transmitters, signal-devices
• A41D 13/11 - Protective face masks, e.g. for surgical use, or for use in foul atmospheres

Abstract

The present invention mainly addresses the problem of providing a novel therapeutic agent for mild cognitive impairment.　As an example of the present invention, citation can be made of a therapeutic agent for mild cognitive impairment or major neurocognitive disorder that is a composition comprising cilostazol or a salt thereof as an active ingredient, said therapeutic agent being to be administered in such a manner that, in order to determine a second dose of the active ingredient to be administered to a subject for treating mild cognitive impairment or major neurocognitive disorder, the active ingredient is administered in an initial dose to the subject prior to the determination, or alternatively that, after administration in the initial dose to the subject, the active ingredient is administered in the second dose to the subject.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides: an antisense oligomer having a base sequence represented by SEQ ID NO: 26, an antisense oligomer having a base sequence represented by SEQ ID NO: 26 with one to six bases substituted, deleted, inserted or added, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof; an oligonucleotide conjugate resulting from the bonding of the foregoing and a molecule that can binds to asialoglycoprotein receptor; and a pharmaceutical composition that includes the foregoing.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 3/06 - Antihyperlipidemics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to identify a marker gene which can be used as an indicator of the severity of pulmonary hypertension (PH).　The present disclosure relates to a use of a gene for aryl hydrocarbon receptor (AHR) or AHR as a marker for PH. The present invention also relates to a method for detecting the marker as an indicator of the severity of PH or an indicator for determining whether a subject is suffering from PH or has the potential to be affected by PH in the future in a specimen isolated from the subject. The present invention also relates to a method for screening for a candidate substance that may be effective for the treatment and/or prevention of PH among from test substances. The present invention also relates to a method for producing a disease model animal of PH.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The present invention addresses the problem of repairing or suppressing DNA damage in cells caused by various types of in vivo and ex vivo factors.　The present invention pertains to an agent that is for repairing or suppressing DNA damage in cells, and that contains adrenomedullin or a modified product thereof having an adrenomedullin activity, or a salt thereof, or an adrenomedullin receptor agonist.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/575 - Hormones
• C12N 15/16 - Hormones

Abstract

Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4′ and 2′ positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 3/06 - Antihyperlipidemics
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention provides a means for treating a symptom of cerebral infarction in a cerebral infarction patient, particularly in an acute stage cerebral infarction patient, without causing undesirable side effects, by optimizing the administration and dosage of a drug that includes, as an active ingredient, adrenomedullin (AM) or a derivative thereof having adrenomedullin activity. One aspect of the present invention relates to a drug for treating a symptom of cerebral infarction in an acute stage cerebral infarction patient, said drug including, as an active ingredient, adrenomedullin or a derivative thereof having adrenomedullin activity, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of any of these.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/575 - Hormones
• C12N 15/16 - Hormones

Abstract

This system (100) for assisting with treatment of stroke comprises a detection device (10), a display unit (30), and an image control unit (20). The image control unit (20) includes: a reception unit (21) that receives first information (41) generated by the detection device (10) and/or second information (42) related to a susceptibility gene, the second information (42) being generated on the basis of the first information (41); and a video output unit (22) that outputs the received first information (41) and/or second information (42) to the display unit (30).

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/03 - Computed tomography [CT]
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The technology relates to a method for inducing cardiomyogenesis comprising administering a therapeutically effective amount of either or both of KLF1 and KLF2b to increase the level of KLF1 and/or KLF2b in the cardiomyocytes thereby inducing cardiomyogenesis.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The technology relates to a method for inducing cardiomyogenesis comprising administering a therapeutically effective amount of either or both of KLF1 and KLF2b to increase the level of KLF1 and/or KLF2b in the cardiomyocytes thereby inducing cardiomyogenesis.

IPC Classes  ?

• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The purpose of the present invention is to provide: a novel hepatic fibrosis-inhibiting agent or brown fat cell-activating agent; and a drug for preventing and/or treating non-alcoholic fatty hepatitis and containing said agent as an active ingredient. The present invention pertains to: a hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin as an active ingredient; and a drug for preventing and/or treating non-alcoholic fatty hepatitis and containing taxifolin as an active ingredient.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to provide: a novel hepatic fibrosis-inhibiting agent or brown fat cell-activating agent; and a drug for preventing and/or treating non-alcoholic fatty hepatitis and containing said agent as an active ingredient. The present invention pertains to: a hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin as an active ingredient; and a drug for preventing and/or treating non-alcoholic fatty hepatitis and containing taxifolin as an active ingredient.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Composite particles, each of which is obtained by forming, on the surface of a gadolinium oxide-containing particle, a cover film that contains a polymer obtained by polymerizing a monomer component containing a monomer having an ethylenically unsaturated bond; a macrophage imaging agent which contains the composite particles; and a method for producing composite particles, wherein a monomer component containing a monomer having an ethylenically unsaturated bond and gadolinium oxide-containing particles are mixed with each other, and after emulsifying the thus-obtained monomer component-containing mixture in the presence of a surfactant and a polymerization initiator in water, the monomer component is polymerized, thereby forming cover films on the surfaces of the gadolinium oxide-containing particles.

IPC Classes  ?

• A61K 49/08 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by the carrier
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

The purpose of the present invention is to provide a novel biomarker for detecting an arteriosclerosis-related disease or for assessing the progress of arteriosclerosis. Specifically, the present invention pertains to a marker which includes Niemann-Pick disease type C2 (NPC2) protein and/or insulin-like growth factor-binding protein 7 (IGFBP7) protein, and which is for detecting an arteriosclerosis-related disease or for assessing the progress of arteriosclerosis.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A myocardial excitation complementation/visualization apparatus includes an acquiring section that acquires intracardiac electrocardiograms of a subject, the intracardiac electrocardiograms being recorded by a recording unit having a plurality of electrodes, a processing section that performs a computation for completing and visualizing a state of excitation in a myocardium of the subject based on the intracardiac electrocardiograms, and a displaying section that displays the state of excitation in the myocardium of the subject based on an output of the processing section. The processing section includes a first generating section, a correcting section, a second generating section, and a third generating section. The displaying section displays a change of the state of excitation in the myocardium of the subject based on the visualized data.

IPC Classes  ?

• A61B 5/361 - Detecting fibrillation
• A61B 5/25 - Bioelectric electrodes therefor
• A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
• A61B 5/349 - Detecting specific parameters of the electrocardiograph cycle
• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/322 - Physical templates or devices for measuring ECG waveforms, e.g. electrocardiograph rulers or calipers
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 18/14 - Probes or electrodes therefor

Abstract

Provided is a method for predicting probability of ischemic stroke onset. A method for predicting a risk of ischemic stroke onset, the method comprising: a detection step of detecting presence or absence of a RNF213 p.R4810K gene variant in a sample derived from a test subject who does not develop ischemic stroke; and a determination step of determining whether a probability of ischemic stroke onset of the test subject is high or not, based on the presence or absence of the RNF213 p.R4810K gene variant in the detection step, and gender information of the test subject. A genetic marker for predicting a risk of ischemic stroke onset using gender information, comprising a RNF213 p.R4810K gene variant. A biomarker for predicting a risk of ischemic stroke onset using gender information, comprising a polypeptide encoded by a RNF213 p.R4810K gene variant.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Provided is a method for predicting the onset risk or onset timing of brain infarction. A method for predicting the onset timing of brain infarction in a subject who has not yet developed brain infarction, said method comprising: a detection step for detecting the presence or absence of an RNF213 p.R4810K gene polymorphism in a sample collected from the subject who has not yet developed brain infarction; and a determination step for determining whether or not the brain infarction onset timing in the subject is earlier than usual depending on the presence or absence of the RNF213 p.R4810K gene polymorphism in the detection step. A genetic marker for predicting brain infarction onset risk, said genetic marker comprising an RNF213 p.R4810K gene polymorphism. A biomarker for predicting brain infarction onset risk, said biomarker comprising a polypeptide encoded by RNF213 p.R4810K gene.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/12 - Genes encoding animal proteins

Abstract

Provided is a novel means for activating an immune response in tumor immunotherapy in which an immune checkpoint inhibitor is used. An immune-checkpoint-inhibitor antitumor effect potentiator having probiotics and prebiotics as active ingredients.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23C 15/00 - ButterButter preparationsMaking thereof
• A23L 2/00 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof
• A23L 2/02 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof containing fruit or vegetable juices
• A23L 2/38 - Other non-alcoholic beverages
• A23L 2/52 - Adding ingredients
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 35/745 - Bifidobacteria
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.

IPC Classes  ?

• A61L 17/14 - Post-treatment to improve physical properties
• A61L 17/10 - At least partly resorbable materials containing macromolecular materials
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/28 - Materials for coating prostheses
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 31/04 - Macromolecular materials
• A61L 31/08 - Materials for coatings
• A61L 33/12 - Polypeptides, proteins or derivatives thereof

Abstract

An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

IPC Classes  ?

• A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61L 27/38 - Animal cells
• A61L 27/50 - Materials characterised by their function or physical properties
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The purpose of the present invention is to provide a novel biomarker with which it is possible to accurately detect an aortic aneurysm. Specifically, the present invention pertains to an aortic aneurysm detection marker which contains an NPC2 (Niemann-Pick disease type C2) protein and/or an IGFBP7 (Insulin-like growth factor-binding protein 7) protein.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided is a novel subcutaneously implanted energizing port which is capable of energization using a relatively simple device and of quickly and stably achieving and maintaining an energized state with high reliability even in an emergency. A subcutaneously implanted energizing port 10 is disposed inside a body and is used for energization inside and outside the body, and has an electrode housing portion 16 in a housing 14 disposed inside the body, the electrode housing portion 16 housing a conductive electrode member 22 and being filled with a filler 24, and having on a wall thereof a power receiving opening 18 which is covered by a pierceable lid member 20.

IPC Classes  ?

• A61M 1/12 - Blood pumps; Artificial hearts; Devices for mechanical circulatory assistance, e.g. intra-aortic balloon pumps implantable into the body
• A61N 1/378 - Electrical supply
• H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling

Abstract

The purpose of the present invention is to provide a tubular artificial organ that has a predetermined strength to be able to retain a lumen without increasing the thickness of the cylinder wall, and that has excellent biocompatibility and growth. This tubular artificial organ 1A is provided with: a tubular tissue body 10 that is formed in an environment in which a biotissue material is present, and is configured with fibrous tissue; and a tubular reinforcement body 20A that is configured with a biodegradable material and is enclosed inside the tubular tissue body 10. The tubular tissue body 10 is formed in a tubular shape by implanting a mold inside an organism and the tubular reinforcement body 20A is preferably enclosed across the entire length. In addition, the tubular tissue body 10 is preferably configured to have a mesh shape by using a biodegradable material.

IPC Classes  ?

• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
• A61F 2/06 - Blood vessels

Goods & Services

Electronic publications, downloadable. Printed matter. Processed meat products; processed seafood; processed vegetables and fruits; pre-cooked curry stew; soup mixes; freeze-dried tofu pieces [Kohri-dofu]; seafood, not live; prepared meals consisting primarily of meat and poultry; prepared meals consisting primarily of seafood; prepared meals consisting primarily of vegetables; prepared meals consisting primarily of seaweed; prepared meals consisting primarily of processed meat, poultry, seafood, or vegetables. Tea; seasonings; spices; rice; flour; sandwiches; Chinese steamed dumplings; sushi; boxed lunches consisting of rice, with added meat, fish or vegetables; boxed lunches consisting of bread, with added meat, fish or vegetables; boxed lunches consisting of pasta, with added meat, fish or vegetables; bread; confectionery; pastries; cereals, processed; processed grains; Chinese stuffed dumplings; pasta sauce; fresh pizzas; hamburgers [sandwiches]; noodles with soup; prepared meals consisting primarily of processed cereals. Arranging, conducting and organization of cooking seminars; arranging, conducting and organization of cooking classes; educational and instruction services relating to cooking; educational and instruction services relating to ingredients; arranging, conducting and organization of cooking contests; providing electronic publications, not downloadable. Services for providing food and drink; providing information about cooking recipes; advice concerning cooking recipes; providing information about cooking recipes via the Internet; advice concerning cooking recipes via the Internet. Medical services; medical testing services for fitness evaluation; nutritional and dietetic consultancy; providing medical information.

Goods & Services

Electronic publications, downloadable. Printed matter. Processed meat products; processed seafood; processed vegetables and fruits; pre-cooked curry stew; soup mixes; freeze-dried tofu pieces [Kohri-dofu]; seafood, not live; prepared meals consisting primarily of meat and poultry; prepared meals consisting primarily of seafood; prepared meals consisting primarily of vegetables; prepared meals consisting primarily of seaweed; prepared meals consisting primarily of processed meat, poultry, seafood, or vegetables. Tea; seasonings; spices; rice; flour; sandwiches; Chinese steamed dumplings; sushi; boxed lunches consisting of rice, with added meat, fish or vegetables; boxed lunches consisting of bread, with added meat, fish or vegetables; boxed lunches consisting of pasta, with added meat, fish or vegetables; bread; confectionery; pastries; cereals, processed; processed grains; Chinese stuffed dumplings; pasta sauce; fresh pizzas; hamburgers [sandwiches]; noodles with soup; prepared meals consisting primarily of processed cereals. Arranging, conducting and organization of cooking seminars; arranging, conducting and organization of cooking classes; educational and instruction services relating to cooking; educational and instruction services relating to ingredients; arranging, conducting and organization of cooking contests; providing electronic publications, not downloadable. Services for providing food and drink; providing information about cooking recipes; advice concerning cooking recipes; providing information about cooking recipes via the Internet; advice concerning cooking recipes via the Internet. Medical services; medical testing services for fitness evaluation; nutritional and dietetic consultancy; providing medical information.

Abstract

This measurement method for quantitatively measuring cerebral blood flow includes: a tracer introduction step for introducing a tracer into a blood vessel; a light irradiation step for irradiating the head with measurement light including a tracer absorption wavelength; a light detection step for detecting the measurement light propagated inside the head and generating a detection signal according to the light intensity of the measurement light; and a calculation step for calculating the cerebral blood flow on the basis of the relative change ΔQ over time of the concentration of the tracer inside cerebral tissue, and a predetermined relationship between the cerebral blood flow and the concentration Pa of the tracer inside a cerebral artery, wherein the relative change ΔQ over time of the concentration of the tracer inside cerebral tissue is obtained on the basis of the detection signal. In the calculation step, the concentration Pa is calculated by using the amplitude of the pulse wave component of the relative change ΔQ.

IPC Classes  ?

• A61B 5/0275 - Measuring blood flow using tracers, e.g. dye dilution
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

A myocardial excitation determining apparatus which can support the determination of excitation dynamics of the myocardium during atrial fibrillation is provided. A myocardial excitation determining apparatus has: an acquiring section 2 which acquires an intracardiac electrocardiogram of a subject; a processing section 3 which computes to produce visualized data indicating a state of excitation in the myocardium, based on the intracardiac electrocardiogram; and a determining section 4 which determines the type of excitation dynamics of the myocardium based on the visualized data.

IPC Classes  ?

• A61B 5/046 - Detecting fibrillation
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/042 - Electrodes specially adapted therefor for introducing into the body

Abstract

The present disclosure aims to provide a method of efficiently manufacturing a cell mass, a cell structure, or a three-dimensional tissue body using a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition. The manufacturing method of a cell mass, a cell structure, or a three-dimensional tissue body of the present disclosure includes seeding and culturing cells on a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12M 1/00 - Apparatus for enzymology or microbiology
• A61L 27/38 - Animal cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

The object of the present invention is to provide a method for producing a cell population comprising mesenchymal stem cells having a high specific growth rate which are useful for promptly producing large amounts of cell formulations. The present invention provides a method for producing a cell population comprising mesenchymal stem cells, comprising: a step of treating a cell population comprising mesenchymal stem cells having different proliferative ability by physical stimulation or chemical stimulation, so as to select mesenchymal stem cells having relatively high proliferative ability, wherein the selected mesenchymal stem cells having relatively high proliferative ability are negative for CD106, and the expression level of a metallothionein family gene is increased in comparison to the expression level thereof in the cell population before the treatment by the physical stimulation or chemical stimulation.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells

Abstract

An oligonucleotide conjugate wherein two or more molecules, said molecules being capable of binding to an asialoglycoprotein receptor, are linearly connected and bound to an oligonucleotide, said oligonucleotide containing a crosslinked synthetic nucleoside having a crosslinked structure between the 4'- and 2'-positions, being complementary to human PCSK9 gene and having an activity of inhibiting the expression of the human PCSK9 gene. The oligonucleotide conjugate according to the present invention is usable in the medicinal field, in particular, for developing and manufacturing therapeutic agents for diseases associated with high LDL cholesterol levels.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 3/06 - Antihyperlipidemics

Abstract

This verification method for an internal organ model comprises: fabricating an organ model A on the basis of 3D organ data that is 3D shape data obtained by measuring the internal organ of a subject; maintaining the organ model A in a substantially similar condition as the internal organ in the body; measuring the organ model maintained in the same condition as the internal organ to obtain 3D model data which serves as the 3D shape data thereof; and displaying an internal organ shape represented by the 3D organ data and an organ model shape represented by the 3D model data to allow for comparison of the shapes.

IPC Classes  ?

• G09B 23/30 - Anatomical models
• A61B 6/03 - Computed tomography [CT]

Abstract

Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood.　In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.

IPC Classes  ?

• A61L 27/28 - Materials for coating prostheses
• A61L 17/10 - At least partly resorbable materials containing macromolecular materials
• A61L 17/14 - Post-treatment to improve physical properties
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 31/04 - Macromolecular materials
• A61L 31/08 - Materials for coatings
• A61L 33/12 - Polypeptides, proteins or derivatives thereof
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof

Abstract

[Problem] To provide an NMUR1 agonist having excellent NMUR1 selectivity, in particular, excellent NMUR1 selectivity at high concentrations. [Solution] A peptide represented by formula (1) set forth in the description, a pharmaceutically acceptable salt thereof, or a prodrug of either.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

[Problem] To provide a peptide that selectively activates neuromedin U receptor 2 and is chemically stable under physiological conditions. [Solution] A peptide represented by formula (1) described in the description.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

To provide a nerve regeneration-inducing tube having improved properties and a material thereof. A compound having a structure in which (A) to (C) are bonded together and (B) and (C) are adjacent to each other: (A) an oligomer comprising at least one member selected from the group consisting of a lactic acid monomer, a glycolic acid monomer and a caprolactone monomer; (B) a hydrophilic segment represented by general formula (1) or (2); and (C) a cell adhesive peptide selected from the group consisting of IKVAV (SEQ ID NO: 1), RGD, RGDS (SEQ ID NO: 2), WQPPRARI (SEQ ID NO: 3), EILDVPST (SEQ ID NO: 4), REDV (SEQ ID NO: 5), LDV, GTPGPQGGIAGQRGVV (SEQ ID NO: 6), GFOGER (SEQ ID NO: 7), YIGSR (SEQ ID NO: 8), RQVFQVAYIIIKA (SEQ ID NO: 9), RKRLQVQLSIRT (SEQ ID NO: 10) and WRTQIDSPLNGK (SEQ ID NO: 11).

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
• A61K 9/70 - Web, sheet or filament bases
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61L 27/00 - Materials for prostheses or for coating prostheses
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

A myocardial excitation complementation/visualization apparatus includes an acquiring section that acquires intracardiac electrocardiograms of a subject, the intracardiac electrocardiograms being recorded by a recording unit having a plurality of electrodes, a processing section that performs a computation for completing and visualizing a state of excitation in a myocardium of the subject based on the intracardiac electrocardiograms, and a displaying section that displays the state of excitation in the myocardium of the subject based on an output of the processing section. The processing section includes a first generating section, a correcting section, a second generating section, and a third generating section. The displaying section displays a change of the state of excitation in the myocardium of the subject based on the visualized data.

IPC Classes  ?

• A61B 5/046 - Detecting fibrillation
• A61B 5/0402 - Electrocardiography, i.e. ECG
• A61B 5/0452 - Detecting specific parameters of the electrocardiograph cycle
• A61B 5/0408 - Electrodes specially adapted therefor
• A61B 5/0456 - Detecting R peaks, e.g. for synchronising diagnostic apparatus
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 18/14 - Probes or electrodes therefor

Abstract

The present invention provides a method for forming a connective tissue body, which enables extending the ranges of design values in terms of shape, dimension, etc., of the connective tissue body. This method comprises: a fat treatment step (step S13) for removing fat contained in a connective tissue body, which is formed in an environment where a biological tissue material is present, from the interior of the connective tissue body while the connective tissue body is being set in a molding tool, and for causing the shape of the connective tissue body to follow the shape of the molding tool; and a bioinert solution treatment step (step S14) for immersing the connective tissue body, together with the molding tool, in a bioinert solution while the connective tissue body is being shaped so as to follow the shape of the molding tool after the fat treatment step.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61F 2/02 - Prostheses implantable into the body

Abstract

A drug for treating or preventing lung damage that contains as an active ingredient an angiotensin type 2 receptor agonist or a pharmaceutically acceptable salt thereof is provided as a novel drug for preventing or suppressing lung damage.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/18 - Sulfonamides
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Provided is a drug that has excellent effect of preventing and/or treating dementia. The drug comprises a carbostyril derivative represented by formula (1) [wherein: R represents a cycloalkyl group; A represents a lower alkyl group; and the bond between the 3- and 4-positions of the carbostyril nucleus is either a single bond or a double bond] and dihydroquercetin.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.

IPC Classes  ?

• C07K 9/00 - Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequenceDerivatives thereof
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• A61L 27/58 - Materials at least partially resorbable by the body
• C07K 14/50 - Fibroblast growth factor [FGF]

Abstract

A tissue body formation device 10 for forming a connective tissue body in an environment where a living tissue material is present is provided with: an inner member 20 having a tissue body formation surface that serves as a surface for forming a connective tissue body; and a covering member which is provided with a covering surface that constitutes an external surface of the tissue body formation device, and that covers a part of the tissue body formation surface. The covering member further has a plurality of connection parts that connect the outer side of the tissue body formation device 10 to the tissue body formation surface. Each of the connection parts has an opening in the covering surface. Each of the openings has a minimum dimension of at least 0.5 mm in a direction along the covering surface. The openings account for 20-40% per unit area of the covering surface.

IPC Classes  ?

• A61F 2/02 - Prostheses implantable into the body
• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts

Abstract

A myocardial excitation determining apparatus which can support the determination of excitation dynamics of the myocardium during atrial fibrillation is provided. A myocardial excitation determining apparatus has: an acquiring section 2 which acquires an intracardiac electrocardiogram of a subject; a processing section 3 which computes to produce visualized data indicating a state of excitation in the myocardium, based on the intracardiac electrocardiogram; and a determining section 4 which determines the type of excitation dynamics of the myocardium based on the visualized data.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/046 - Detecting fibrillation
• A61N 1/40 - Applying electric fields by inductive or capacitive coupling

Abstract

The purpose of the present invention is to provide a method for efficiently producing a cell cluster, cell structure, or three-dimensional tissue body using a culture surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition. This method for producing a cell cluster, cell structure, or three-dimensional tissue body is characterized in that cells are seeded and cultivated on a culture surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0786 - MonocytesMacrophages
• C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells

Abstract

The present invention provides a prophylactic/therapeutic agent for arteriosclerosis, cardiovascular diseases, cerebrovascular diseases, and fatty liver, and is characterized by containing a mangostana pericarp extract as an active ingredient.

IPC Classes  ?

• A61K 36/38 - Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A drug combining (A) a natriuretic peptide receptor GC-A agonist, with, as (B) an anti-malignant tumor agent, a compound having anti-microtubule action, or a PD-1 pathway inhibitor [(B')]. By administering the drug at least 5 days before administering the (B) anti-malignant tumor agent, the natriuretic peptide receptor GC-A agonist effect is exhibited, and the (B) anti-malignant tumor agent can effectively reach the inside of the tumor cells via the bloodstream, thereby making the drug useful as an anti-malignant tumor treatment drug having a strong effect.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 38/22 - Hormones
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/58 - Atrial natriuretic factor complexAtriopeptinAtrial natriuretic peptide [ANP]CardionatrinCardiodilatin

Abstract

The present invention provides a stent that can obtain sufficient strength while an inner side of the stent is easily endothelialized and moreover, can prevent occlusion of a branch blood vessel. Specifically, a stent body capable of diameter expansion is provided. A tubular film 3 is held by the stent body. In the tubular film 3, a plurality of communication holes 4 communicating between an inside and an outside are formed. Band-shaped portions 7 and 8 are formed between the communication holes 4 adjacent to each other. A wide-width portion and a narrow portion are not generated in the band-shaped portions 7 and 8. Strength of a part of the band-shaped portions 7 and 8 is not lowered. Generation of the wide-width portion in the band-shaped portions 7 and 8 is prevented.

IPC Classes  ?

• A61F 2/91 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts

Abstract

The present invention addresses the problem of providing a method for producing mesenchymal stem cells having a high specific growth rate, the method being useful for quickly producing large quantities of cell preparations. The present invention provides a method for producing a cell population that includes mesenchymal stem cells, wherein the method for producing a cell population is characterized by including a selection step for selecting mesenchymal stem cells that have a relatively high growth capacity by treating a cell population that includes mesenchymal stem cells of different growth capacities by physical stimulation or chemical stimulation, the mesenchymal stem cells that have a relatively high growth capacity thereby selected being CD106-positive, and the expression level of metallothionein family genes being increased over that prior to treatment by physical stimulation or chemical stimulation.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 17/06 - Antipsoriatics
• A61P 37/02 - Immunomodulators

Abstract

The present invention provides a novel medicinal drug for preventing or inhibiting acute kidney injury, the medicinal drug containing an angiotensin II receptor antagonist or a pharmacologically acceptable salt thereof as an active ingredient, and being used for treatment or prevention of acute kidney injury. Also provided is a novel method for preventing or inhibiting acute kidney injury, comprising administering an effective dosage of an angiotensin II receptor antagonist or a pharmacologically acceptable salt thereof to a patient in combination with an anticancer agent and/or an antitumor agent.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/18 - Sulfonamides
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The purpose of the present invention is to provide a cell culture container by which a large amount of small sized cell structures can be easily prepared. A cell culture container provided with a plurality of first coated areas, said areas being coated with a temperature-responsive polymer or a temperature-responsive polymer composition, in a culture face thereof, characterized in that the surface zeta potential of the first coated areas is 0-50 mV.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/22 - Petri dishes

Abstract

A cell separation device comprising a container, in which a liquid supplied from above can be filled, and a partition mechanism, which partitions the inside of the container into upper and lower parts, said cell separation device being characterized in that: the partition mechanism is provided with a partition plate which has through holes and a barrier wall which is in contact with the partition plate and provided with holes communicating with the inside of the lower surface of the upper inside part of the container; and, when the partition plate rotates around the center in the long axial direction of the container as a rotational axis, the upper inside part and the lower inside part of the container are switchable to a communicated state and a blocked state. In the cell separation device according to the present invention, a cell-containing liquid can be easily filled without causing disturbance on the boundary surface between the cell-containing liquid and a separation liquid and, after centrifuging, layered cells can be easily separated and, moreover, target cells can be harvested at a high purity.

IPC Classes  ?

• C12M 1/28 - Inoculator or sampler being part of container
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Provided are a myocardial excitement interpolation/visualization device with which a state of myocardial excitement can be viewed in real time, and a myocardial excitement detection device with which sites of myocardial excitement can be detected more accurately. The device is provided with an acquisition unit (2) for acquiring an intercardiac electrocardiogram recorded by multiple electrodes, a computing unit (3) for performing computations to interpolate and visualize a state of myocardial excitement on the basis of the intercardiac electrocardiogram, and a display unit (4) for displaying the state of myocardial excitement. The computational unit (3) has a first generation unit (11) for generating an action potential waveform for each of a plurality of intercardiac electrocardiograms, a correction unit (13) for performing correction to harmonize the amplitudes of each unit waveform included in the action potential waveforms, a second generation unit (14) for generating shift waveforms differing in time phase from the corrected action potential waveforms, and a third generation unit (16) for creating phase diagrams on the basis of the corrected action potential waveforms and the shift waveforms, and generating visualization data representing a state of myocardial excitement in a test subject, on the basis of the phase diagrams. The display unit (4) displays changes in the state of myocardial excitement of a test subject, on the basis of the visualization data.

IPC Classes  ?

• A61B 5/0402 - Electrocardiography, i.e. ECG
• A61B 5/0452 - Detecting specific parameters of the electrocardiograph cycle

Abstract

An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

IPC Classes  ?

• A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61L 27/38 - Animal cells
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61L 27/50 - Materials characterised by their function or physical properties

Abstract

The present invention provides: a substrate for forming an artificial valve, the substrate allowing a connective tissue to be easily inserted into a flap-forming space to thereby reduce the time needed for forming the flap; and an artificial valve. Specifically, a columnar substrate body 6 is provided. A plurality of concave parts 7 are formed on the external circumferential surface of the substrate body 6. A cover substrate 9 is mounted on the substrate body 6. The concave part 7 is covered with the cover substrate 9 to define a flap-forming space 8. An opening 10 for inserting the connective tissue 2 is defined between the edge of the cover substrate 9 and the rim of the concave part 7. A slit 11 is formed in the cover substrate 9 to allow communication between the flap-forming space 8 and the outside of the substrate. The slit 11 is formed parallel to a substrate central axis 15 and is long enough to reach the edge of the cover substrate 9. The substrate 1 for forming an artificial valve is placed in an environment where biological tissue material is present. The connective tissue 2 is formed on the surface of the substrate. The cover substrate 9 is pulled away from the substrate body 6 in the direction of the substrate central axis. The connective tissue 2 which is removed from the substrate is used as an artificial valve 5.

IPC Classes  ?

• A61F 2/06 - Blood vessels

Abstract

The present invention provides a connective tissue formation substrate with which it is possible to form film-like connective tissue of a desired thickness such that both sides have a desired surface condition, without requiring a long time for the formation of connective tissue. Specifically, two tissue formation surfaces 2a, 2b face each other and sandwich a tissue formation space 3 therebetween. The tissue formation space 3 is communicated with the outside of the substrate by the formation of a slit 9 in the tissue formation surface 2b. A connective tissue formation substrate 1 is installed in an environment in which a biological tissue sample is present. Connective tissue enters the tissue formation space 3 from the slit 9. Film-like connective tissue is formed such that both sides match the substrate surface.

IPC Classes  ?

• A61F 2/06 - Blood vessels
• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
• A61F 2/10 - Hair or skin implants
• A61F 2/24 - Heart valves

Abstract

The present invention provides a stent capable of obtaining both easy endothelialisation and sufficient strength inside a stent and also capable of preventing blockage of branch blood vessels. Specifically, a diameter-enlargeable stent main body is provided. A tubular film (3) is held by the stent main body. A plurality of through-holes (4) that penetrate inside and outside are formed in the tubular film (3). Band-shaped sections (7, 8) are formed between adjacent through-holes (4). Sections having wider and narrower widths are not generated in the band-shaped sections (7, 8). The strength of one section of the band-shaped sections (7, 8) is not reduced. Formation of wide sections in the band-shaped sections (7, 8) is prevented.

IPC Classes  ?

• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61F 2/07 - Stent-grafts

Abstract

The purpose of the present invention is to provide a simple, highly safe method with which it is possible to recover mononuclear cells stably and at high efficiency from body fluids including mononuclear cells such as bone marrow aspirate, peripheral blood, and cord blood and removing the granulocytes. The present invention provides a granulocyte removal method that feeds a body fluid at a linear velocity of less than 0.33 cm/min to a container housing cellulose acetate having a proportion of hydroxyl groups substituted by acetyl groups of 23-54% of the total hydroxyl groups so that the total surface area is 157-627 cm2.

IPC Classes  ?

• A61M 1/02 - Blood transfusion apparatus
• A61K 35/14 - BloodArtificial blood
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61P 7/08 - Plasma substitutesPerfusion solutionsDialytics or haemodialyticsDrugs for electrolytic or acid-base disorders, e.g. hypovolemic shock